GlassScriptPhysician profile
Andrew Parrish Holt
NPI 1316367071
$69,267.91
in general payments reported to CMS, 2019-2025
19 companies · $44K in 2025
The $44K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.66 · 2021: $1,715 · 2022: $642 · 2023: $1,114 · 2024: $22K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Food and Beverage: $3,794 · Consulting Fee: $3,628 · Travel and Lodging: $1,086 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,180.00 |
| Food and Beverage | $3,794.17 |
| Consulting Fee | $3,627.50 |
| Travel and Lodging | $1,086.48 |
| Education | $207.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $62,074.73 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Actelion Pharmaceuticals US, INC. | $3,698.20 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Alon Medical Technology | $1,200.00 | 2021 | |
| United Therapeutics Corporation | $868.17 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Glaxosmithkline, LLC. | $356.50 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $175.39 | 2022-2025 | |
| Lungpacer Medical USA INC | $174.28 | 2025 | Aeropace Neurostimulation Console |
| Bayer Healthcare Pharmaceuticals INC. | $162.08 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.29 | 2021-2023 | Ofev |
| Insmed, INC. | $116.77 | 2023-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $51.69 | 2024-2025 | Winrevair, Zerbaxa |
| Abbvie INC. | $51.19 | 2024-2025 | |
| Pfizer INC. | $48.77 | 2021-2022 | |
| Amgen INC. | $32.62 | 2025 | Tezspire |
| Grifols USA, LLC | $32.55 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $31.08 | 2021-2022 | |
| Harmony Biosciences LLC | $30.75 | 2021-2022 | |
| Genentech USA, INC. | $18.68 | 2023 | Xolair |
| Baxter Healthcare | $17.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.